AEROVATE THERAPEUTICS INC (AVTE)
US0080641071 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||||||
| EBITDA YoY % growth | -3.33M | -8.89M -166.97% | -23M -158.72% | -53.17M -131.17% | -81.313M -52.93% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -3.33M | -8.89M -166.97% | -23.02M -158.94% | -53.24M -131.28% | -81.409M -52.91% | N/A -17.44% | N/A 19.81% | N/A -11.65% | N/A 75.55% | N/A 17.87% | N/A 9.82% | N/A 4.23% | N/A -91.34% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.11 -28.69% | -2.88 -36.49% | N/A 6.85% | N/A 73.83% | N/A -106.30% | N/A -195.77% | N/A 18.10% | N/A 84.01% | N/A 712.73% | N/A 78.04% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.39 46.70% | -0.30 63.75% | -0.25 70.94% | -0.18 67.21% | -0.12 68.97% | -0.81 -167.80% | -0.84 -234.69% | -0.87 -372.22% | -0.90 -633.33% |
| Revenue Q2Q % growth | 13.711M | 13.78M | 13.849M | 13.918M | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -22.714M -2.94% | -13.26M 46.14% | -10.404M 60.24% | -8.466M 51.37% | -6.12M 73.06% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.56 21.13% | -0.59 | 0.03 | 5.75% |
| Q2 2024 Q2Q % growth | -0.86 -13.16% | -0.84 | -0.02 | -2.57% |
| Q1 2024 Q2Q % growth | -0.83 -23.88% | -0.78 | -0.05 | -6.37% |
| Q4 2023 Q2Q % growth | -0.74 -21.31% | -0.72 | -0.02 | -2.52% |
| Q3 2023 Q2Q % growth | -0.71 -26.79% | -0.71 | 0.00 | -0.65% |
| Q2 2023 Q2Q % growth | -0.76 -55.10% | -0.71 | -0.05 | -7.05% |
| Q1 2023 Q2Q % growth | -0.67 -48.89% | -0.61 | -0.06 | -9.48% |
| Q4 2022 Q2Q % growth | -0.61 -74.29% | -0.63 | 0.02 | 3.20% |
| Q3 2022 Q2Q % growth | -0.56 -115.38% | -0.51 | -0.05 | -10.19% |
| Q2 2022 Q2Q % growth | -0.49 97.94% | -0.46 | -0.03 | -5.64% |
| Q1 2022 Q2Q % growth | -0.45 | -0.28 | -0.17 | -58.98% |
| Q4 2021 Q2Q % growth | -0.35 | -0.31 | -0.04 | -11.59% |
| Q3 2021 Q2Q % growth | -0.26 | -0.27 | 0.01 | 1.96% |
| Q2 2021 Q2Q % growth | -23.80 | -0.16 | -23.64 | -14,793.30% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 51.16% | 5.57% | 5.57% |
| Revenue | N/A | N/A | N/A | N/A |